Возможности и перспективы использования отечественного пробиотика на основе спорообразующих бактерий в педиатрической практике
DOI:
https://doi.org/10.15574/79068Ключевые слова:
дисбактериоз, пробиотик, спорообразующие бактерии, Биоспорин-БиофармаАннотация
Представленный научный обзор отечественной и зарубежной медицинской литературы посвящен анализу эффективности отечественного современного спорообразующего самоэлиминирующегося пробиотика «Биоспорин-Биофарма« в педиатрической практике.
Библиографические ссылки
Courvalin P, Gueimonde M et al. 2008. Antibiotikorezistentnost probiotikov: dovodyi «za» i «protiv». Zdorovia Ukrainy. 7/1 kvit: 12—13.
Belousova EYu. 2015. Algoritmyi naznacheniya probiotikov u detey. Zdorovia Ukrainy. 3(34) ver: 10—11.
Ligeza K, Chaplinskiy V, Sorokulova I i dr. 2004. Biosporin Biofarma pri lechenii kishechnyih infektsiy. Doktor. 3: 54—56.
Borshch SK. 2013. The differential use Biosporin for antagonistic elimination grampositive bacterium for treatment intestinale diseases. Sovremennaya pediatriya. 3(51): 57—60.
Borshch SK. 2008. Dyferentsiiovane vykorystannia probiotykiv dlia antahonistychnoho vplyvu na hrampozytyvni bakterii u likuvanni kyshkovykh infektsii i syndromu dysbakteriozu kyshechnyka. Liky i zhyttia. 6: 23—31.
Korneva VV, Kozachuk VG, Boyarskaya EA, Kapichina MA. 2014. Veduschie proyavleniya hronicheskih zaporov u detey — vozmozhnyie puti ih razresheniya. Sovremennaya pediatriya. 6: 92-96.
Gopchuk ЕN, Makovskaya TYe. 2014. Vaginal candidiasis — a modern alternative to traditional therapy. Health of woman. 10(96): 53—56.
Dzigal RP, Verba NV. 2013. Application of Biosporin for the treatment of acute intestinal infections in pregnant women. Sovremennaya pediatriya. 7(55): 42—46.
Sorokulova IВ, Safronova LA. et al. 2014. Correction of disturbances in the microbiocenosis of the intestine in newborn infants by the administration of Biosporin. Sovremennaya pediatriya. 3(59): 121—124.
Lezhenko HO, Pashkova OE. 2014. Dosvid zastosuvannia preparatu Biosporin-Biofarma v korektsii funktsionalnykh rozladiv shlunkovo-kyshkovoho traktu u ditei hrudnoho viku. Zdorove rebenka. 7(58): 7—10.
Marushko RV, Marushko TL. 2014. Effectiveness of probiotic containing bacillus subtilis and bacillus licheniformis in infants with bowel diseases. Sovremennaya pediatriya. 8(64): 90—97.
Pohilenko VD, Perelyigin VV. 2007. Probiotiki na osnove sporoobrazuyuschih bakteriy i ih bezopasnost. Him i biolog bezopasnost. 2—3: 27—33.
Ershova IB, Mochalova AA, Osipova TV i dr. 2015. Preparatyi, vosstanavlivayuschie mikrobiotsenoz, kak etiotropnaya terapiya ostryih kishechnyih infektsiy u detey. Aktual infektolohiia. 2(7): 12—17.
Pro zatverdzhennia unifikovanykh klinichnykh protokoliv medychnoi dopomohy ditiam iz zakhvoriuvanniamy orhaniv travlennia. Nakaz MOZ Ukrainy vid 29.01.2013 № 59. http://www.moz.gov.ua.
Probiotiki v sovremennoy gastroeenterologii i pediatrii: mirovyie tendentsii glazami ukrainskih uchenyih. Mater III nauchnoy sessii Instituta gastroenterologii NAMN Ukrainyi «Noveyshie tehnologii v klinicheskoy i teoreticheskoy gastroenterologii», 18—19 iyunya, g. Dnepropetrovsk. Zdorovia Ukrainy. 2015. 11—12 (360—361): 4—5.
Korniychuk OP, Burova LM, Lavrik GS. et al. 2013. Biosporin antimicrobial activity: study in vitro. Sovremennaya pediatriya. 6(54): 92—97.
Rudenko AV, Pasiechnikov SP, Mitchenko MV. 2015. Feasibility of etiotropic therapy of women of reproductive age with acute uncomplicated pyelonephritis as well as acute chronic pyelonephritis and assident infectious and inflammatory processes of reproductive tracts, caused by associated agents of different taxonomic position. Health of woman. 1(97): 34—37.
Skryipnik IN, Maslova AS. 2009. Sovremennyie sporoobrazuyuschie probiotiki v klinicheskoy praktike. Suchasna hastroenterol. 3(47): 81—86.
Skryipnik IN, Maslova AS. 2013. Effektivnost i bezopasnost sovremennyih sporoobrazuyuschih probiotikov pri lechenii narusheniy mikrobiotsenoza kishechnika. Zdorovia Ukrainy. 22(323) lystop: 28—30.
Smirnov VV. 2001. Antibiotiki i/ili probiotiki: razmyishleniya i faktyi. Likuvannia ta Diahnostyka. 3: 8—16.
Sorokulova IB. 2007. Vliyanie probiotikov iz batsill na funktsionalnuyu aktivnost makrofagov. Ros vestn perinatol i pediatrii. 2: 28—30.
Sorokulova IB. 2008. Korrektsiya Biosporinom narusheniy mikrobiotsenoza kishechnika u novorozhdennyih i detey grudnogo vozrasta. Ros vestn perinatol i pediatrii. 5: 17—19.
Tkach SM, Puchkov KS, Sizenko AK. 2014. Kishechnaya mikrobiota v norme i pri patologii. Sovremennyie podhodyi k diagnostike i korrektsii kishechnogo disbioza. Kiev: 227.
Chaplinskiy VYa. 2004. Biosporin — effektivnyiy lechebnyiy preparat na osnove batsill. Doktor. 4: 75—76.
Chernyakova VI, Bereza NM, Selezneva SI. 1998. Bakteriologicheskaya i immunobiologicheskaya effektivnost biosporina pri nespetsificheskom yazvennom kolite. Provizor. 11: 12—14.
Shabliy TP. 2013. Chronic recurrent vulvovaginal candidiasis: Innovative Approaches in the treatment of. Health of woman. 8(84): 62—65.
Yankovskiy DS, Dyiment GS. 2008. Mikroflora i zdorove cheloveka. Kyiv, Chervona Ruta Turs: 552.
American Gastroenterological Association. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002. 123: 108—139.
Dunne C, Murphy L, Flynn S. 1999. Probiotics: from myth to reality. Demonstration functionality in animal models disease and in humen clinical trials. Zhurn mikrobiol, epidemiol i immunobiol. 76;1—4: 279—292.
EFSA. 2005. Opinion of the FEEDAP Panel on the updating of the criteria used in the assessment of bacteria for risistance to antibiotics of human or veterinary importance. EFSA J. 223: 112.
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition / European Society for Pediatric Infectious Diseases Evidence — Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe: Update 2014. Copyright 2014 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited. JPGN. 2014. 59;1: 132—152.
Fuller R, Gibson GR. 1998. Probiotics and prebiotics: microflora management for improved gut health. Clin Microbiol Infect. 4: 477—480.
Gibson GR, Roberfroid MB. 1995. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 125: 1401—1412.
Hong HA, Duc LH, Cutting SM. 2005.The use of bacterial sporeformers as probiotics. FEMS Microbiol Rev. 29;4: 813—835.
Hyman PE, Milla PJ, Benninga МА. 2006. Childhood Functional Gastrointestinal Disorders: Neonate. Toddler Gastroenterology. 130(5): 1519—1526. http://dx.doi.org/10.1053/j.gastro.2005.11.065
Katz Т, Demain AE. 1997. The peptide antibiotics of Bacillus: chemistry, biogenesis and possible functions. Bacteriol Rev. 41: 449.
Lebenthal E, Lebenthal Y. 2013. Probiotiki: kontseptsiya lechebnogo primeneniya, ozhidayuschaya svoego priznaniya. Zhurn mikrobiol, epidemiol i immunobiol. 4: 88—90.
Mazza P. 1994. The use of bacillus subtilis as an antidiarrhoeal microorganism. Bull Chim Farm. 133: 3—18.
Pediatric gastroenterology drug formulary. The Therapeutics Subcommittee of the Patient Care Committee, North American. Society for Pediatric Gastroenterology and Nutrition. July. 2000.
Pinchuk IV, Bressollier P. 2004. In Vitro aktivnost probiticheskogo shtamma Bacillus subtilis 3, napravlennaya protiv. Helicobacter pylori, obuslovlena sekretsiey antibiotikov. RMN, Universite Claude Bernard, Lyon 1, ESPCPE Lyon. 69622 Vxllerbanne Cedex, Франция.
Sanders ME, Morelli L, Tompkins TA. 2003. Sporeformers as human probiotics: Bacillus, Sporolactobacillus, and Brevibacillus. Compr Rev Food Sci and Food Safety. 2: 101—102.
Stein T. 2005. Bacillus subtillis antibiotics: structures, syntheses and specific functions. Mol Microbiol. 56: 845—857.
Von Wright A. 2005. Regulating the safety of probiotics — the European approach. Curr Pharm Des. 11: 17—23.
